CPHI India and PMEC India 2026, organised by Informa Markets in India, will bring together stakeholders from across the pharmaceutical value chain through two specialised exhibitions in Delhi-NCR. In a new dual-venue format, CPHI India will be held from November 23–25 at India International Convention and Expo Centre (IICC), Yashobhoomi, Dwarka, while PMEC India will take place from November 24–26 at India Expo Centre and Mart (IEML), Greater Noida.
The exhibitions are expected to feature more than 2,000 exhibitors, attract over 50,000 pharmaceutical professionals and visitors, and welcome participants from more than 120 countries. The expanded format will connect pharmaceutical manufacturers, ingredient suppliers, contract development and manufacturing organisations (CDMOs), machinery manufacturers and technology providers.
CPHI India will cover active pharmaceutical ingredients (APIs), finished dosage formulations, excipients, natural extracts, fine chemicals, intermediates and CDMO services. PMEC India will focus on pharmaceutical machinery, processing and packaging equipment, laboratory and analytical systems, cleanroom technology and manufacturing solutions.
To support business development, the Connections Programme will facilitate curated, pre-arranged meetings between eligible buyers and exhibitors. The Startup Market package will provide eligible businesses with opportunities to present their solutions and engage with prospective customers and partners. Visitors will be able to access both exhibitions with a single badge, supported by complimentary shuttle services between the two venues.
The exhibitions come at a time when India’s pharmaceutical industry is expanding its manufacturing base and international presence. The sector recorded an annual turnover of ₹4.72 lakh crore in FY2024–25 and ranks third globally by production volume. With more than 3,000 companies and 10,500 manufacturing units, India exported pharmaceuticals worth approximately US$30.5 billion during the year, registering 9.4% year-on-year growth and reaching 191 countries. The domestic market is estimated at around US$60 billion and is projected to reach US$130 billion by 2030.
The event will also address manufacturing priorities such as API development, advanced formulations, process efficiency, automation, packaging, laboratory infrastructure and quality assurance. North India’s pharmaceutical clusters, including Baddi-Barotiwala-Nalagarh and Kala Amb in Himachal Pradesh, Selaqui in Uttarakhand, and manufacturing centres in Haryana and Uttar Pradesh, represent an important regional base for the sector.
A two-day Pharma Connect conference on November 23–24 will bring together industry speakers, including Dr. Declan Byrne of the European Directorate for the Quality of Medicines & HealthCare, Devender Kumar Singh of Pfizer Inc., and Vaibhavi Shah and Dr. Ankur Shah of Invengene. Discussions will cover India’s ambitions in API manufacturing, the CDMO sector, regulation and cell and gene therapies.
Other programme highlights include the India Pharma Awards 2026, Pharma Leadership Exchange and Women in Pharma at CPHI India, alongside a CXO Roundtable and Regulators Panel Discussion at PMEC India. Exhibitors include Dr. Reddy’s Laboratories, Akums Drugs and Pharmaceuticals, Morepen Laboratories, Hetero Labs, Fette Compacting, ACG Pam Pharma Technologies, IMA-PG India and Parle Global Technologies. Association partners include OPPI, IPEC India, BDMAI, GPMA and KDPMA.
Yogesh Mudras, Managing Director, Informa Markets in India, said, “India’s pharmaceutical industry is strengthening its manufacturing capabilities and global competitiveness. Government data shows that the pharmaceutical drugs PLI scheme generated approximately 1.15 lakh jobs by March 2026, reflecting the sector’s manufacturing potential. With investment in APIs, formulations, automation and quality systems becoming increasingly important, CPHI India and PMEC India 2026 will connect manufacturers, ingredient suppliers, CDMOs and technology providers through specialised platforms and targeted business interactions. The event is designed to help industry stakeholders explore partnerships, identify solutions and pursue new business opportunities across the pharmaceutical value chain.”
Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia, said India’s pharmaceutical industry was moving towards high-value, innovation-led and sustainable manufacturing. He highlighted the growing importance of domestic capabilities in APIs, advanced intermediates and CDMO services, supported by the company’s technology platforms, research and development capabilities and investments of approximately ₹20,000 million over the past three years. He added that AI-enabled manufacturing and the integration of more than 35% green energy would support the company’s sustainability and competitiveness priorities.
Pankaj Banerjee, Head of Global Exports Business and Senior General Manager, Hamdard Laboratories India, highlighted the growth prospects for the pharmaceutical, AYUSH and herbal wellness sectors. He pointed to the need for stronger domestic API manufacturing, investment in medicinal plant cultivation, standardised extracts, GMP-compliant production and research and development. At CPHI India 2026, Hamdard will present products from its Medicine Division and its Pure&Pristine Beauticeuticals range, alongside recently launched products. The company’s priorities include expanding sterile herbal products, strengthening global quality compliance and entering more than 50 SRM/SRA markets.
The CPHI & PMEC India expo continues to serve as a catalyst for innovation, collaboration, and transformative growth in the pharmaceutical and biopharma sectors, reinforcing India’s position as a global leader in healthcare solutions. CPHI India and PMEC India 2026 will convene key stakeholders from across the pharmaceutical ingredients, contract manufacturing and production technology sectors, offering a platform to explore innovative solutions, build business partnerships and identify growth opportunities in domestic and international markets.